Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05814705

The Effects of Protein Supplementation With or Without Urolithin A During Single-leg Immobilization

Comparison of High-protein Formulation With/Without Urolithin a During a Unilateral Knee Immobilization: a Pilot Proof-of-concept Trial

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
McMaster University · Academic / Other
Sex
Male
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

There are times in life when people cannot use their muscles, such as during illness or injury. Muscle and mitochondria (the 'energy factory' in cells) health decline very quickly when people cannot use their muscles, but certain foods can help reduce these declines. Recent research suggests that Urolithin A, which is a natural compound that can be produced after eating pomegranates, nuts, and berries, improves muscle health. In this study, the investigators aim to investigate if a protein beverage (standard care during disuse) with or without Urolithin A can reduce or prevent the loss of muscle health while wearing a knee brace (muscle disuse).

Detailed description

After participants provide informed consent to participate and are deemed eligible for the study (Day 0), participants will sequentially complete the three phases of this study: 1. RUN-IN phase: participants continue habitual lifestyle (Day 7-Day 14 \[1 week\]) 2. IMMOBILIZATION phase: participants undergo 2 weeks of unilateral knee immobilization (Day 14-Day 28 \[2 weeks\]) 3. RECOVERY phase: participants return to habitual lifestyle (Day 28-Day 35 \[1 week\]) Participants will consume their randomly assigned supplement daily during all three phases.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTProtein supplementReady-to-drink protein beverage consumed once daily for 28 days
DIETARY_SUPPLEMENTProtein supplement with Urolithin AReady-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days

Timeline

Start date
2023-06-01
Primary completion
2024-05-31
Completion
2025-04-30
First posted
2023-04-18
Last updated
2024-10-02

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05814705. Inclusion in this directory is not an endorsement.